Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|April 30, 2026

The BioPharm Brief: Metabolic Phase III Progress, HER2 Oncology Momentum, and US Manufacturing Expansion Drive Industry Scale

In today’s podcast, we see clinical durability, targeted combination strategies, and domestic production investment highlighting integrated approaches to meeting rising global demand for complex therapies.

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research, regulatory progress, and global manufacturing strategy. Today’s update highlights advances in metabolic disease, oncology regulatory momentum, and continued investment in US-based drug production infrastructure.

First, Zealand Pharma and Roche are advancing petrelintide, an amylin analog, into phase 3 trials for chronic weight management, with studies expected to begin in the second half of 2026. The once-weekly therapy demonstrated double-digit weight loss with placebo-like tolerability in earlier trials, positioning it as a potential alternative or complement to existing incretin-based treatments. The program will evaluate efficacy, safety, and long-term adherence in patients with obesity or overweight, reflecting growing competition in the rapidly expanding metabolic disease market.

In oncology, FDA granted priority review to a HER2-targeted treatment strategy for gastroesophageal adenocarcinoma, supported by phase 3 data demonstrating improved progression-free and overall survival outcomes compared with standard-of-care regimens. The designation accelerates regulatory timelines and underscores continued progress in precision oncology, particularly in HER2-driven cancers where targeted and combination approaches are reshaping frontline treatment paradigms.

Meanwhile, Novartis has finalized a major expansion of its US manufacturing footprint with the addition of a seventh facility, strengthening its end-to-end drug production capabilities. The move is part of a broader multibillion-dollar investment strategy aimed at increasing domestic production capacity across active pharmaceutical ingredients, biologics, and advanced therapies. Expanding integrated manufacturing networks is becoming increasingly important as companies seek to improve supply chain resilience and meet rising global demand for complex medicines.

Taken together, today’s developments highlight a common theme across the industry: scaling innovation requires not only strong clinical data and regulatory momentum, but also the infrastructure and manufacturing capabilities to deliver therapies efficiently at a global level.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Summary of key developments

  • Petrelintide enters phase 3 as competition intensifies in chronic weight management.
  • FDA priority review advances HER2-targeted strategies in gastroesophageal cancer.
  • Novartis expands US manufacturing to strengthen end-to-end production capacity.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more